Inhibits DPP-4, prolongs action of incretin hormones, enhancing insulin release and reducing glucagon.

Saxagliptin is a DPP-4 inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The recommended dosage of saxagliptin tablet is 2.5 mg or 5 mg orally once daily taken regardless of meals. Do not cut, crush, or chew saxagliptin tablets.

Common: upper respiratory tract infection, urinary tract infection, headache.

Other risks: peripheral edema (especially with TZDs), lymphopenia, hypoglycemia, rash.

Post-marketing: pancreatitis, rhabdomyolysis, bullous pemphigoid, severe joint pain.

Hypersensitivity reactions to saxagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).

Pancreatitis: Monitor for severe abdominal pain; discontinue if suspected.

Heart Failure: Higher hospitalization rate noted in trials. Monitor at-risk patients closely.

Hypoglycemia: Especially when used with insulin or sulfonylureas.

Hypersensitivity Reactions: Discontinue if symptoms occur.

Arthralgia: Severe joint pain reported; consider discontinuation.

Bullous Pemphigoid: May require dermatologic evaluation.